返回 Agenda
Market Access Roundtable Update: Financing of Therapeutics in Europe – Beyond Traditional Approaches
Session Chair(s)
Indranil Bagchi, PHD, MSC
Global Head, Pricing & Market Access
GSK, United States
Inka Heikkinen, MBA, MSC
Regulatory Policy Lead
Lundbeck, Denmark
This session is being co-developed by DIA and the Boston Consulting Group Market Access Roundtable working group, a group consisting of industry leaders who recently worked on Alternative Funding Models. The problem statement of the white paper reflects the European health care systems’ ability to provide an equal access to care and the funding gap for the emerging innovative treatments, fueled by the silos existing within the HTA system and resource inefficiency. The potential solutions could be co-payment, private insurance, employer-supported models and new payment models.
Speaker(s)
ndustry View for Financing of Novel Therapeutics in Europe
Indranil Bagchi, PHD, MSC
GSK, United States
Global Head, Pricing & Market Access
Patient View for Financing of Novel Therapeutics in Europe
David Haerry
EATG, Switzerland
Patient Advocate
Regulator/Payer View for Financing of Novel Therapeutics in Europe
Luca Pani, MD
University of Miami, United States
Former, AIFA; Professor, Department of Psychiatry and Behavioral Sciences